These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 30917858)
1. Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage. Muller P; Coates PJ; Nenutil R; Trcka F; Hrstka R; Chovanec J; Brychtova V; Vojtesek B J Ovarian Res; 2019 Mar; 12(1):30. PubMed ID: 30917858 [TBL] [Abstract][Full Text] [Related]
2. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
3. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
5. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer]. Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477 [No Abstract] [Full Text] [Related]
6. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer. Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726 [TBL] [Abstract][Full Text] [Related]
7. Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer. Rhodes A; Vallikkannu N; Jayalakshmi P Br J Biomed Sci; 2017 Apr; 74(2):65-70. PubMed ID: 28367736 [TBL] [Abstract][Full Text] [Related]
8. Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder. Ahmed MAH; Ali MH; Abbas HH; Elatrash GA; Foda AAM Pathol Oncol Res; 2020 Jan; 26(1):411-418. PubMed ID: 30382527 [TBL] [Abstract][Full Text] [Related]
9. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325 [TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Skírnisdóttir I; Seidal T Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012 [TBL] [Abstract][Full Text] [Related]
11. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer. Ramalingam P Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153 [TBL] [Abstract][Full Text] [Related]
12. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. McCluggage WG Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157 [TBL] [Abstract][Full Text] [Related]
13. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Diebold J; Baretton G; Felchner M; Meier W; Dopfer K; Schmidt M; Löhrs U Am J Clin Pathol; 1996 Mar; 105(3):341-9. PubMed ID: 8602616 [TBL] [Abstract][Full Text] [Related]
14. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature. Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633 [TBL] [Abstract][Full Text] [Related]
15. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725 [TBL] [Abstract][Full Text] [Related]
17. AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation. Armes JE; Davies CM; Wallace S; Taheri T; Perrin LC; Autelitano DJ Pathology; 2013 Jan; 45(1):49-54. PubMed ID: 23222243 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal. Karamurzin Y; Leitao MM; Soslow RA Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975 [TBL] [Abstract][Full Text] [Related]
19. TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. Aleskandarany MA; Negm OH; Rakha EA; Ahmed MA; Nolan CC; Ball GR; Caldas C; Green AR; Tighe PJ; Ellis IO Breast Cancer Res Treat; 2012 Nov; 136(2):419-27. PubMed ID: 23053644 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study. Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]